US4021492A
(en)
*
|
1975-03-24 |
1977-05-03 |
Sandoz, Inc. |
Dibromination process
|
SE414305B
(sv)
*
|
1976-08-25 |
1980-07-21 |
Astra Laekemedel Ab |
Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
|
US4318791A
(en)
*
|
1977-12-22 |
1982-03-09 |
Ciba-Geigy Corporation |
Use of aromatic-aliphatic ketones as photo sensitizers
|
FR2430933A1
(fr)
*
|
1978-07-13 |
1980-02-08 |
Synthelabo |
Derives de propiophenone et leur application en therapeutique
|
US4347257A
(en)
*
|
1979-10-09 |
1982-08-31 |
Burroughs Wellcome Co. |
Prolactin suppression in mammals
|
FR2486074A1
(fr)
*
|
1979-12-14 |
1982-01-08 |
Lafon Labor |
Derives de fluorophenacyl-amine, leur procede de preparation et leur application en therapeutique
|
DE3167150D1
(en)
*
|
1980-04-14 |
1984-12-20 |
Wellcome Found |
New unlabelled and radioactive labelled derivatives of butylamino propiophenone, their preparation, immunogens obtained from the unlabelled derivatives and a process for immunogen preparation, antisera raised using the immunogens and a method for raising antisera, a radioimmunoassay method and a test kit for use in the assay method
|
ATE8987T1
(de)
*
|
1981-03-23 |
1984-09-15 |
Laboratoire L. Lafon Societe Anonyme Dite: |
Fluorphenacyl-amin-derivate und ihre therapeutische verwendung.
|
JPS57169450A
(en)
*
|
1981-04-13 |
1982-10-19 |
Lafon Labor |
Fluorophenacyl-amine derivative and application to remedy
|
US4393078A
(en)
*
|
1982-03-15 |
1983-07-12 |
Burroughs Wellcome Co. |
Bupropion and ethanol
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
US4507323A
(en)
*
|
1984-07-25 |
1985-03-26 |
Burroughs Wellcome Co. |
Treatment of psychosexual dysfunctions
|
FR2569184A1
(fr)
*
|
1984-08-20 |
1986-02-21 |
Lafon Labor |
Derives de 1-(aminophenyl) therapeutique et leur procede de preparation
|
US5236922A
(en)
*
|
1984-08-20 |
1993-08-17 |
Laboratoire L. Lafon |
Method for treating depression using 1-(aminophenyl)-2-aminopropanone derivatives
|
FR2569185B1
(fr)
*
|
1984-08-20 |
1986-09-05 |
Lafon Labor |
Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique
|
GB9217295D0
(en)
*
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
US5358970A
(en)
*
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5753712A
(en)
*
|
1994-02-18 |
1998-05-19 |
Pinsker; Walter |
Treatment of migraine headaches and formulations
|
WO1995022324A1
(en)
*
|
1994-02-18 |
1995-08-24 |
Walter Pinsker |
Treatment of migraine headaches and formulations
|
US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6458374B1
(en)
|
1998-01-29 |
2002-10-01 |
Sepracor, Inc. |
Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
|
CA2318920A1
(en)
*
|
1998-01-29 |
1999-08-05 |
James W. Young |
Pharmaceutical uses of optically pure (-)-bupropion
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
EP2301537A1
(en)
*
|
2002-05-17 |
2011-03-30 |
Duke University |
Zonisamide for the treatment of obesity
|
KR101228376B1
(ko)
|
2002-07-18 |
2013-01-31 |
사이토스 바이오테크놀로지 아게 |
합텐-캐리어 컨쥬게이트 및 그의 용도
|
WO2004024674A1
(en)
*
|
2002-09-10 |
2004-03-25 |
Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. |
Process for the preparation of bupropion hydrochloride
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
ITMI20030762A1
(it)
*
|
2003-04-11 |
2004-10-12 |
Erregierre Spa |
Processo di cristallizzazione del bupropione cloridrato.
|
CN1784221B
(zh)
|
2003-04-29 |
2010-07-07 |
奥雷西根治疗公司 |
影响体重减轻的组合物
|
WO2004112756A1
(en)
*
|
2003-06-26 |
2004-12-29 |
Isa Odidi |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
AU2004271800A1
(en)
|
2003-09-12 |
2005-03-24 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
EP1691811B1
(en)
|
2003-12-11 |
2014-07-23 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
EP1734955A2
(en)
|
2004-01-13 |
2006-12-27 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
|
WO2005107806A1
(en)
*
|
2004-04-21 |
2005-11-17 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP1896002A4
(en)
*
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
|
CA2614289A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
BRPI0617382A2
(pt)
*
|
2005-10-14 |
2017-07-11 |
H Lundbeck As |
Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
|
US20070112075A1
(en)
*
|
2005-10-14 |
2007-05-17 |
Forest Laboratories, Inc. |
Stable pharmaceutical formulations containing escitalopram and bupropion
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
MX337422B
(es)
|
2005-11-22 |
2016-03-04 |
Orexigen Therapeutics Inc |
Composiciones y metodos para incrementar la sencibilidad a la insulina.
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007079470A2
(en)
*
|
2006-01-03 |
2007-07-12 |
Algebra, Inc. |
Therapeutic amine-arylsulfonamide conjugate compounds
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
WO2007117581A2
(en)
*
|
2006-04-06 |
2007-10-18 |
Collegium Pharmaceutical, Inc. |
Stabilized transdermal bupropion preparations
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
US10960077B2
(en)
*
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
EP2068872A1
(en)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
TWI609702B
(zh)
|
2006-11-09 |
2018-01-01 |
歐瑞根治療有限公司 |
層狀醫藥調配物
|
KR20140088619A
(ko)
|
2006-11-09 |
2014-07-10 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
WO2008156749A1
(en)
*
|
2007-06-18 |
2008-12-24 |
The General Hospital Corporation |
Combination therapy for depression
|
CN100560563C
(zh)
*
|
2007-07-06 |
2009-11-18 |
浙江普洛医药科技有限公司 |
盐酸安非他酮的合成方法
|
US20090076161A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bupropion
|
US20090148541A1
(en)
*
|
2007-10-16 |
2009-06-11 |
Duke University |
Compositions and methods for the treatment of seborrhea
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
WO2010004386A2
(en)
*
|
2008-06-16 |
2010-01-14 |
Glenmark Generics Limited |
Amorphous bupropion hydrobromide and preparation thereof
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CA2758774C
(en)
|
2009-04-15 |
2015-02-03 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
KR101841442B1
(ko)
|
2010-01-11 |
2018-03-23 |
오렉시젠 세러퓨틱스 인크. |
주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
|
CA2875056C
(en)
|
2012-06-06 |
2024-03-26 |
Orexigen Therapeutics, Inc. |
Methods of treating overweight and obesity
|
US11129826B2
(en)
|
2013-11-05 |
2021-09-28 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US11433067B2
(en)
|
2013-11-05 |
2022-09-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11541048B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9198905B2
(en)
|
2013-11-05 |
2015-12-01 |
Antecip Bioventures Ii Llc |
Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
|
US10980800B2
(en)
|
2013-11-05 |
2021-04-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10933034B2
(en)
|
2013-11-05 |
2021-03-02 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457023B1
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11253491B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966941B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llp |
Bupropion as a modulator of drug activity
|
US10874665B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273134B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11617747B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123344B2
(en)
|
2013-11-05 |
2021-09-21 |
Axsome Therapeutics, Inc. |
Bupropion as a modulator of drug activity
|
US10105327B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
|
US11571417B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10966974B2
(en)
|
2013-11-05 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11364233B2
(en)
|
2013-11-05 |
2022-06-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11497721B2
(en)
|
2013-11-05 |
2022-11-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11357744B2
(en)
|
2013-11-05 |
2022-06-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426370B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576909B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11596627B2
(en)
|
2013-11-05 |
2023-03-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11058648B2
(en)
|
2013-11-05 |
2021-07-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10881657B2
(en)
|
2013-11-05 |
2021-01-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10813924B2
(en)
|
2018-03-20 |
2020-10-27 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US11524007B2
(en)
|
2013-11-05 |
2022-12-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11478468B2
(en)
|
2013-11-05 |
2022-10-25 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11439636B1
(en)
|
2013-11-05 |
2022-09-13 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11234946B2
(en)
|
2013-11-05 |
2022-02-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11426401B2
(en)
|
2013-11-05 |
2022-08-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11253492B2
(en)
|
2013-11-05 |
2022-02-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11517543B2
(en)
|
2013-11-05 |
2022-12-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10105361B2
(en)
|
2013-11-05 |
2018-10-23 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11541021B2
(en)
|
2013-11-05 |
2023-01-03 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9700528B2
(en)
|
2013-11-05 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11291665B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9861595B2
(en)
|
2013-11-05 |
2018-01-09 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11298352B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10894046B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9763932B2
(en)
|
2013-11-05 |
2017-09-19 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10898453B2
(en)
|
2013-11-05 |
2021-01-26 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11576877B2
(en)
|
2013-11-05 |
2023-02-14 |
Antecip Bioventures Ii Llc |
Bupropion as modulator of drug activity
|
US20160361305A1
(en)
|
2013-11-05 |
2016-12-15 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US11141416B2
(en)
|
2013-11-05 |
2021-10-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10780064B2
(en)
|
2019-01-07 |
2020-09-22 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10688066B2
(en)
|
2018-03-20 |
2020-06-23 |
Antecip Bioventures Ii Llc |
Bupropion and dextromethorphan for treating nicotine addiction
|
US20200338022A1
(en)
|
2019-01-07 |
2020-10-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285146B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10080727B2
(en)
|
2013-11-05 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11311534B2
(en)
|
2013-11-05 |
2022-04-26 |
Antecip Bio Ventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11298351B2
(en)
|
2013-11-05 |
2022-04-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10786469B2
(en)
|
2013-11-05 |
2020-09-29 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US9474731B1
(en)
|
2013-11-05 |
2016-10-25 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11617728B2
(en)
|
2013-11-05 |
2023-04-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US12109178B2
(en)
|
2013-11-05 |
2024-10-08 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10512643B2
(en)
|
2013-11-05 |
2019-12-24 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US10894047B2
(en)
|
2013-11-05 |
2021-01-19 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11007189B2
(en)
|
2013-11-05 |
2021-05-18 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874663B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11344544B2
(en)
|
2013-11-05 |
2022-05-31 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11285118B2
(en)
|
2013-11-05 |
2022-03-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10940124B2
(en)
|
2019-01-07 |
2021-03-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9867819B2
(en)
|
2013-11-05 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11213521B2
(en)
|
2013-11-05 |
2022-01-04 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9707191B2
(en)
|
2013-11-05 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US20220233470A1
(en)
|
2013-11-05 |
2022-07-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11419867B2
(en)
|
2013-11-05 |
2022-08-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9968568B2
(en)
|
2013-11-05 |
2018-05-15 |
Antecip Bioventures Ii Llc |
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
|
US11382874B2
(en)
|
2013-11-05 |
2022-07-12 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11534414B2
(en)
|
2013-11-05 |
2022-12-27 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10772850B2
(en)
|
2013-11-05 |
2020-09-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11123343B2
(en)
|
2013-11-05 |
2021-09-21 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11191739B2
(en)
|
2013-11-05 |
2021-12-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10874664B2
(en)
|
2013-11-05 |
2020-12-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9402843B2
(en)
|
2013-11-05 |
2016-08-02 |
Antecip Bioventures Ii Llc |
Compositions and methods of using threohydroxybupropion for therapeutic purposes
|
US10799497B2
(en)
|
2013-11-05 |
2020-10-13 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US10864209B2
(en)
|
2013-11-05 |
2020-12-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9457025B2
(en)
|
2013-11-05 |
2016-10-04 |
Antecip Bioventures Ii Llc |
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
|
US11571399B2
(en)
|
2013-11-05 |
2023-02-07 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11096937B2
(en)
|
2013-11-05 |
2021-08-24 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US10945973B2
(en)
|
2013-11-05 |
2021-03-16 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11273133B2
(en)
|
2013-11-05 |
2022-03-15 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11291638B2
(en)
|
2013-11-05 |
2022-04-05 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11185515B2
(en)
|
2013-11-05 |
2021-11-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11590124B2
(en)
|
2013-11-05 |
2023-02-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11147808B2
(en)
|
2013-11-05 |
2021-10-19 |
Antecip Bioventures Ii Llc |
Method of decreasing the fluctuation index of dextromethorphan
|
US11197839B2
(en)
|
2013-11-05 |
2021-12-14 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11090300B2
(en)
|
2013-11-05 |
2021-08-17 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11229640B2
(en)
|
2013-11-05 |
2022-01-25 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US10966942B2
(en)
|
2019-01-07 |
2021-04-06 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11207281B2
(en)
|
2013-11-05 |
2021-12-28 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11510918B2
(en)
|
2013-11-05 |
2022-11-29 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11065248B2
(en)
|
2013-11-05 |
2021-07-20 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11020389B2
(en)
|
2013-11-05 |
2021-06-01 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US20160324807A1
(en)
|
2013-11-05 |
2016-11-10 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US9408815B2
(en)
|
2013-11-05 |
2016-08-09 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
WO2015095713A1
(en)
|
2013-12-20 |
2015-06-25 |
Deuterx, Llc |
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
|
CN106699527A
(zh)
*
|
2016-12-07 |
2017-05-24 |
三峡大学 |
一种间氯苯丙酮的合成方法
|
US10925842B2
(en)
|
2019-01-07 |
2021-02-23 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|